SBM.V - Sirona Biochem Corp.

TSXV - TSXV Delayed Price. Currency in CAD
0.4200
0.0000 (0.00%)
At close: 9:30AM EST
Stock chart is not supported by your current browser
Previous Close0.4200
Open0.4200
Bid0.4000 x N/A
Ask0.4150 x N/A
Day's Range0.4200 - 0.4200
52 Week Range0.0650 - 0.6900
Volume500
Avg. Volume143,885
Market Cap92M
Beta (5Y Monthly)0.31
PE Ratio (TTM)N/A
EPS (TTM)-0.0210
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2006-12-27
1y Target Est0.73
  • CNW Group

    /R E P E A T -- Sirona Biochem Reports 100% Safety in First Tox Study for Increased Concentration of TFC-1067/

    In anticipation of a clinical study in Q2 of 2020, Sirona has completed the first required toxicity study for the increased dose (0.4%) of TFC-1067. TFC-1067 .4% was found to be a non-irritant in 100% of subjects in the patch test. In a similar study1 (published in the Annals of Dermatology 2017), 20 volunteers were patch-tested with varying levels of hydroquinone (HQ) alone and in combination with retinoic acid (RA).

  • Sirona Biochem Reports 100% Safety in First Tox Study for Increased Concentration of TFC-1067
    CNW Group

    Sirona Biochem Reports 100% Safety in First Tox Study for Increased Concentration of TFC-1067

    In anticipation of a clinical study in Q2 of 2020, Sirona has completed the first required toxicity study for the increased dose (0.4%) of TFC-1067. TFC-1067 .4% was found to be a non-irritant in 100% of subjects in the patch test. In a similar study1 (published in the Annals of Dermatology 2017), 20 volunteers were patch-tested with varying levels of hydroquinone (HQ) alone and in combination with retinoic acid (RA).

  • CNW Group

    /R E P E A T -- Sirona Biochem Proceeds to First Clinical Tests for Higher Concentrations to Increase Commercial Value of Skin Lightening Compound TFC-1067/

    Sirona's scientific team at TFChem and the Senior Toxicologist at CEHTRA (www.cehtra.com) have reviewed recent in-vitro safety assays and verified that the compound can be tested at double the prior concentration. The Human Patch Test for cutaneous irritation will be conducted under physician supervision at Cosmepar (www.cosmepar.fr/en/) in France . Cosmepar's specialized services include evaluating the tolerance of cosmetic products.

  • Sirona Biochem Proceeds to First Clinical Tests for Higher Concentrations to Increase Commercial Value of Skin Lightening Compound TFC-1067
    CNW Group

    Sirona Biochem Proceeds to First Clinical Tests for Higher Concentrations to Increase Commercial Value of Skin Lightening Compound TFC-1067

    Sirona's scientific team at TFChem and the Senior Toxicologist at CEHTRA (www.cehtra.com) have reviewed recent in-vitro safety assays and verified that the compound can be tested at double the prior concentration. The Human Patch Test for cutaneous irritation will be conducted under physician supervision at Cosmepar (www.cosmepar.fr/en/) in France . Cosmepar's specialized services include evaluating the tolerance of cosmetic products.

  • CNW Group

    /R E P E A T -- Sirona Biochem Hires Shanghai-based Chemistry Engineer to Select Local Manufacturer for Skin-Lightening Compound TFC-1067/

    Mr. Pinqiao Zhao is a university-trained chemist who has extensive experience with fluorination chemistry and manufacturing. Mr. Zhao has participated in multiple publications and is an accomplished innovator in chemical manufacturing.

  • Sirona Biochem Hires Shanghai-based Chemistry Engineer to Select Local Manufacturer for Skin-Lightening Compound TFC-1067
    CNW Group

    Sirona Biochem Hires Shanghai-based Chemistry Engineer to Select Local Manufacturer for Skin-Lightening Compound TFC-1067

    Mr. Pinqiao Zhao is a university-trained chemist who has extensive experience with fluorination chemistry and manufacturing. Mr. Zhao has participated in multiple publications and is an accomplished innovator in chemical manufacturing.

  • Sirona Biochem: Agreement Signing Ceremony with Rodan + Fields at Cosmetic 360 Conference in Paris
    CNW Group

    Sirona Biochem: Agreement Signing Ceremony with Rodan + Fields at Cosmetic 360 Conference in Paris

    Rodan + Fields, the leading skin care brand in the United States 1, is preparing to incorporate novel ingredient TFC-1067 into their product lines. Backed by extensive scientific research, TFC-1067 is clinically proven to be safe and effective at reducing the visibility of dark spots, brightening and evening skin tone. Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy , will introduce TFChem, the wholly owned French subsidiary of Sirona Biochem, which has created breakthrough skin care solutions using platform-based technology.

  • Is Sirona Biochem (CVE:SBM) Weighed On By Its Debt Load?
    Simply Wall St.

    Is Sirona Biochem (CVE:SBM) Weighed On By Its Debt Load?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • CNW Group

    /R E P E A T -- Sirona Biochem Signs Binding Term Sheet with Cosmetic Distributor in China/

    Tinyi will have distribution rights within Asia as well as exclusive rights for China . Tinyi, founded in 2006, is a well-established cosmetic ingredient distributor headquartered in Guangzhou , the cosmetic valley in China .

  • Sirona Biochem Signs Binding Term Sheet with Cosmetic Distributor in China
    CNW Group

    Sirona Biochem Signs Binding Term Sheet with Cosmetic Distributor in China

    Tinyi will have distribution rights within Asia as well as exclusive rights for China . Tinyi, founded in 2006, is a well-established cosmetic ingredient distributor headquartered in Guangzhou , the cosmetic valley in China .

  • CNW Group

    /R E P E A T -- Sirona Biochem to Present Additional Clinical Results of TFC-1067 at Cosmetic 360 in Paris, France/

    Since 2015, Cosmetic 360 has become an exclusive international event that allows the most influential cosmetic companies and industry decision makers to access the latest advancements in science. Dr. Deliencourt-Godefroy will be joined by lab colleague Dr. Jocelyne Legoedec as well as Ms. Michelle Seltenrich , Vice President Operations, to present the most recent advancements of Sirona's novel skin lightener, TFC-1067. Thanks to compelling clinical evidence of superiority to selectively remove dark spots in comparison to a leading brand containing hydroquinone, previous challenges to partnering have been overcome and Sirona is now well positioned with TFC-1067.

  • Sirona Biochem to Present Additional Clinical Results of TFC-1067 at Cosmetic 360 in Paris, France
    CNW Group

    Sirona Biochem to Present Additional Clinical Results of TFC-1067 at Cosmetic 360 in Paris, France

    Since 2015, Cosmetic 360 has become an exclusive international event that allows the most influential cosmetic companies and industry decision makers to access the latest advancements in science. Dr. Deliencourt-Godefroy will be joined by lab colleague Dr. Jocelyne Legoedec as well as Ms. Michelle Seltenrich , Vice President Operations, to present the most recent advancements of Sirona's novel skin lightener, TFC-1067. Thanks to compelling clinical evidence of superiority to selectively remove dark spots in comparison to a leading brand containing hydroquinone, previous challenges to partnering have been overcome and Sirona is now well positioned with TFC-1067.

  • /R E P E A T -- Sirona Biochem Signs Definitive License & Supply Agreement with Skincare Industry Leader Rodan + Fields/
    CNW Group

    /R E P E A T -- Sirona Biochem Signs Definitive License & Supply Agreement with Skincare Industry Leader Rodan + Fields/

    Rodan and Fields will be the first to market for a consumer product utilizing TFC-1067 in certain countries including United States . Under the terms of the agreement, Sirona will receive an upfront and milestone payments as well as on-going revenue in return for the manufacture and supply of TFC-1067, a novel, new skin brightening ingredient, for use by Rodan + Fields on a non-exclusive basis and Rodan + Fields will launch a new product incorporating the ingredient.  Further details of this agreement will remain confidential for strategic reasons.

  • Sirona Biochem Signs Definitive License & Supply Agreement with Skincare Industry Leader Rodan + Fields
    CNW Group

    Sirona Biochem Signs Definitive License & Supply Agreement with Skincare Industry Leader Rodan + Fields

    Rodan and Fields will be the first to market for a consumer product utilizing TFC-1067 in certain countries including United States . Under the terms of the agreement, Sirona will receive an upfront and milestone payments as well as on-going revenue in return for the manufacture and supply of TFC-1067, a novel, new skin brightening ingredient, for use by Rodan + Fields on a non-exclusive basis and Rodan + Fields will launch a new product incorporating the ingredient.  Further details of this agreement will remain confidential for strategic reasons.

  • Sirona Biochem Adopts Shareholder Rights Plan
    CNW Group

    Sirona Biochem Adopts Shareholder Rights Plan

    The Rights Plan is subject to acceptance by the TSX Venture Exchange ("TSXV") and ratification by Sirona's shareholders within six months. If the shareholders do not ratify the Rights Plan at the AGM, the Rights Plan and all the rights outstanding at the time will terminate.

  • Sirona Biochem Announces Successful Close of Oversubscribed Private Placement
    CNW Group

    Sirona Biochem Announces Successful Close of Oversubscribed Private Placement

    The Private Placement consists of 3,750,000 units, (the "Units") at a price of $0.40 per Unit.  Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 3 years from the date of issue at a price of $0.60 per share subject to an acceleration clause. All securities issued under the Private Placement are subject to statutory hold periods expiring on November 10, 2019 . Proceeds will be used to establish Asia -based manufacturing for TFC-1067 as well as to accelerate Sirona's anti-ageing and anti-wrinkle projects.

  • Sirona Biochem Announces Proposed Strategic Equity Investment
    CNW Group

    Sirona Biochem Announces Proposed Strategic Equity Investment

    The private placement consists of 2,500,000 units, (the "Units") at a price of $0.40 per Unit.  Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 3 years from the date of issue at a price of $0.60 per share subject to an acceleration clause. The Company is proposing to pay a finder's fee to an agent or agents that assist in procuring the proceeds of the offering. Such Fee shall consist of a cash fee equal to no more than 8% of the total proceeds of the Private Placement placed by such finder and warrants up to 8% of the number of Units the finder sells in the Private Placement (the "Finder's Warrants").

  • /R E P E A T -- Sirona Biochem Releases CEO Letter to Shareholders/
    CNW Group

    /R E P E A T -- Sirona Biochem Releases CEO Letter to Shareholders/

    VANCOUVER , July 4, 2019 /CNW/ - Sirona Biochem Corp. (SBM.V) (ZSB.F) ("Sirona") is pleased to provide a corporate update from the Company's CEO, Dr. Howard Verrico , regarding its plans both near and long term in the following Q&A format. Why are the details limited on the clinical trial update from Wanbang?

  • Sirona Biochem Releases CEO Letter to Shareholders
    CNW Group

    Sirona Biochem Releases CEO Letter to Shareholders

    VANCOUVER , July 4, 2019 /CNW/ - Sirona Biochem Corp. (SBM.V) (ZSB.F) ("Sirona") is pleased to provide a corporate update from the Company's CEO, Dr. Howard Verrico , regarding its plans both near and long term in the following Q&A format. Why are the details limited on the clinical trial update from Wanbang?

  • /R E P E A T -- Sirona Biochem Announces SGLT2 Inhibitor Development Progress/
    CNW Group

    /R E P E A T -- Sirona Biochem Announces SGLT2 Inhibitor Development Progress/

    Wanbang and Sirona are unable to comment further on the details of the progress for strategic as well as competitive reasons. Sirona Biochem's SGLT2 inhibitor, TFC-039, was licensed to Wanbang Biopharmaceuticals, a wholly owned subsidiary of Shanghai Fosun Pharmaceutical Group in 2014 with exclusive rights for China . In exchange for this license, Wanbang Biopharma will provide upfront and milestone payments of up to US$9.5M in addition to royalty payments for product sales in China .

  • Sirona Biochem Announces SGLT2 Inhibitor Development Progress
    CNW Group

    Sirona Biochem Announces SGLT2 Inhibitor Development Progress

    Wanbang and Sirona are unable to comment further on the details of the progress for strategic as well as competitive reasons. Sirona Biochem's SGLT2 inhibitor, TFC-039, was licensed to Wanbang Biopharmaceuticals, a wholly owned subsidiary of Shanghai Fosun Pharmaceutical Group in 2014 with exclusive rights for China . In exchange for this license, Wanbang Biopharma will provide upfront and milestone payments of up to US$9.5M in addition to royalty payments for product sales in China .

  • Did You Miss Sirona Biochem's (CVE:SBM) Whopping 538% Share Price Gain?
    Simply Wall St.

    Did You Miss Sirona Biochem's (CVE:SBM) Whopping 538% Share Price Gain?

    Sirona Biochem Corp. (CVE:SBM) shareholders might be concerned after seeing the share price drop 12% in the last week...

  • Do Institutions Own Sirona Biochem Corp. (CVE:SBM) Shares?
    Simply Wall St.

    Do Institutions Own Sirona Biochem Corp. (CVE:SBM) Shares?

    If you want to know who really controls Sirona Biochem Corp. (CVE:SBM), then you'll have to look at the makeup of its...

  • Sirona Biochem Reports 2019 AGM Voting and CEO Update
    CNW Group

    Sirona Biochem Reports 2019 AGM Voting and CEO Update

    The total number of shares represented by shareholders present in person and by proxy at the meeting was 32,141,666 million representing 15.47% of Sirona's issued and outstanding Common Shares. All of the matters put forward before shareholders for consideration and approval as set out in the Company's Management Information Circular dated 22nd of May, 2019, were approved by the requisite majority of votes cast at the Meeting.

  • /R E P E A T -- Sirona Biochem Signs Term Sheet for TFC-1067 with Skincare Industry Leader Rodan + Fields/
    CNW Group

    /R E P E A T -- Sirona Biochem Signs Term Sheet for TFC-1067 with Skincare Industry Leader Rodan + Fields/

    This term sheet covers all material terms and conditions of a definitive agreement with San Francisco -based, industry leading, Rodan + Fields. The definitive agreement is expected to be signed in Q3/2019. The term sheet stipulates Sirona will become a manufacturer and supplier of TFC-1067 for use by Rodan + Fields on a non-exclusive basis in its current markets ( USA , Canada and Australia ) as well as future regions.